bullous pemphigoid
Conditions
Interventions
Dupi-retrospective:We will retrospectively recruit patients with bullous pemphigoid who received dupilumab treatment and their serum sample information at the outpatient department of Peking Universit
Dupi-prospective:A prospective study will include patients receiving dupilumab treatment and their serum sample information at the outpatient department of Peking University First Hospital from June 2
Sponsors
Peking university first hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Patients: 1. Age between 18 and 80 years. 2. Meets the following diagnostic criteria for bullous pemphigoid: a. Clinical manifestations: Symmetrical blisters and bullae formation on normal skin or edematous erythema, which may be accompanied by itching and urticarial-like rashes. b. Histopathology: Subepidermal blister formation with infiltration of eosinophils or neutrophils. c. Immunological indicators: Positive anti-BP180 and/or BP230 antibodies detected in serum by enzyme-linked immunosorbent assay (ELISA); or linear IgG/C3 deposition along the epidermal basement membrane zone observed by direct immunofluorescence (DIF). 3. Voluntary participation in this study with the provision of signed informed consent.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1. Previous use of biological agents such as rituximab, omalizumab, or other similar biologics. 2. Usage of systemic glucocorticoids for a duration of =3 months; or received oral systemic steroids, immunosuppressants, biologics, intravenous immunoglobulin (IVIG) therapy, or plasmapheresis within the past month; or application of topical glucocorticoid treatment for =6 months. 3. Long-term use of DPP-4 inhibitors for diabetes management or PD-1 checkpoint inhibitors, with an inability to discontinue these medications. 4. Patients with severe active infections. 5. Concurrent diagnosis of psoriasis, linear IgA bullous dermatosis, pemphigoid gestationis, mucous membrane pemphigoid, dermatitis herpetiformis, or lupus erythematosus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| anti-BP180 IgG Antibody;29 inflammatory cytokine/chemokine biomarkers; | — |
Countries
China
Contacts
Public ContactMingyue Wang
Department of Dermatology, Peking University First Hospital
Outcome results
None listed